Market research
ADTX Aditxt Inc.
OTC USD Healthcare
Latest close
As of 26 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 998K
- P/E ratio
- 0.0
- Analyst target
- 61
- Dividend yield
- Not available
- Beta
- -17.5
Profile
Instrument facts
- Exchange
- OTC
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 998K
- P/E ratio
- 0.0
- Analyst target
- 61
- Dividend yield
- Not available
- Beta
- -17.5
About
About Aditxt Inc.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Research context
Aditxt Inc. appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ADTX discussion.
5 years, 6 months ago
ADiTx Therapeutics, Inc is currently in a long term downtrend where the price is trading 2.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, ADiTx Therapeutics, Inc gets an overall score of 1/5.